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www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMreplacement in high operative risk patients. The currently most widely used valves are
Edwards SAPIEN XT and Medtronic CoreValve.
Methods: We analyzed data of 424 consecutive patients undergoing trans-femoral
TAVI at the Tel Aviv Medical Center, and performed a comparison between the two
bioprostheses regarding pre-procedural patient’s characteristics, procedural data and
1 year post-procedural clinical outcome.
Results: CoreValve and the Edwards SAPIEN prostheses were implanted in 320 and
104 patients, respectively. CoreValve patients were older (835 vs. 817 years,
p¼0.026), with lower estimated glomerular ﬁltration rate (6018 vs. 6620 ml/min/
1.73m2, p¼0.009), higher EuroSCORE (25 14 vs. 20 13 %, p¼0.015) and a
smaller pre-procedural aortic valve area (0.69 0.18 vs. 0.74 0.19 cm2, p¼0.035).
No other differences regarding patient’s characteristics were observed. Compared to
TAVI with Edwards prosthesis, Corevalve procedures had shorter ﬂuoroscopy
time (16.46 vs. 17.55 minutes, p¼0.02), higher patient’s cumulative radiation
dose (1477755 vs. 1197591 Gy, p< 0.001), and less contrast media (14340 vs.
15740 ml, p¼0.001). Device success was similar among the two valves (95 vs. 96%,
p¼0.57). Mortality (in hospital and after 1 year) was similar among the valves
implanted (2.5 vs. 2.9%, p¼0.83, and 15.7 vs. 19%, p¼0.54). CoreValve patients had
higher rates of permanent pacemaker implantation (24.4 vs. 11.5%, p¼0.005), and
post-procedural blood transfusion (40 vs. 25%, p¼0.014). No difference was observed
regarding vascular complication (18 vs. 21%, p¼0.49), stroke (1.3 vs. 1.9%, p¼0.61),
moderate or severe paravalvular leak (2 vs. 2.6%, p¼0.766), or acute kidney injury of
any stage (13.8 vs. 19.6%, p¼0.15).
Conclusions: Despite differences in patient’s and procedural characteristics between
CoreValve and Edwards Sapiens TAVI, device success and mortality rates were
similar.
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Background: Transcatheter aortic valve replacement (TAVR) is primarily performed
in non-operable and high-risk surgical patients, including those of advanced age. The
clinical proﬁles, procedural characteristics, and outcomes of nonagenarians undergo-
ing TAVI have not been reported.
Methods: We evaluated 72 patients >90 years old with severe symptomatic aortic
stenosis undergoing TAVR. Baseline characteristics at time of TAVR were collected
which include co-existing conditions as well as periprocedural ﬁndings and Valve
Academic Research Consortium-2 (VARC-2) complications. Death at 30-days and 1-
year were also evaluated.
Results: The cohort represents 47% males (84% Caucasian; age 932 years) with
mean Society of Thoracic Surgeons (STS) and EuroSCORE of 12.34.6 and
26.822.5, respectively. Non-operable indication was 55%, and the majority received
a balloon expandable valve (85%). While hypertension was very prevalent (92%),
other STS risk factors were considerably lower than anticipated: diabetes (21%),
COPD (17%; 4.5% severe), cerebral vascular disease (19%), peripheral arterial disease
(27%), prior myocardial infarction (16%), prior coronary artery bypass (14%), or
glomerular ﬁltration rate < 60 mL/min (50%). Mean body mass index was
23.93.7kg/m2. Transfemoral procedural duration was 111.3  48 minutes with
VARC-2 device success of 95.9%. Post-TAVR length of stay was 86 days. High
rates of major vascular complications were present and a large proportion of deaths
occurred early (table).Adverse Events Following TAVR
In-Hospital Outcomes
VARC-2 major vascular complication 15.5%
VARC-2 major bleed 2.7%
Ischemic stroke 2.7%
Pacemaker implantation 5.5%
Worsening heart failure 30.1%
Moderate or severe aortic insufﬁciency 1.6%
Death 6.8%
Death at 30-days 11.0%
Death at 1-year 26.0%
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patients a decade younger, likely the result of a favorable pre-procedural health history
in this cohort. Thus, TAVR should not be withheld from nonagenarians.
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Background: Aortic valve stenosis (AVS) can be complicated by bleeding associated
with acquired type 2A von Willebrand syndrome. The association of AVS and
gastrointestinal bleeding from angiodysplasia is deﬁned as Heyde’s syndrome. We
sought to evaluate the impact of TAVI on primary hemostasis disorders and to assess
its effectiveness to treat Heyde’s syndrome.
Methods: We prospectively enrolled 49 consecutive patients with severe AVS
addressed for TAVI in our institution. Biological primary hemostasis parameters were
assessed at baseline and one week after the procedure.
Results: We identiﬁed 1 (2%) patient with Heyde’s syndrome, and 11 patients
(22.4%) with a ratio vWF:CB/vWF:Ag under 0.7, compatible with type 2A vWF
syndrome. At baseline, a signiﬁcant link between vWF abnormalities and the severity
of AVS was evidenced: mean aortic transvalvular gradient was negatively correlated
with the levels of vWF antigen (vWF:Ag) (r¼ -0.29, p< 0.05), vWF ristocetin
cofactor activity (vWF:RCo) (r¼-0.402, p¼0.006) and vWF collagen-binding activity
(vWF:CB) (r¼-0.441, p¼0.005). One week after the procedure, a signiﬁcant increase
of vWF:Ag, vWF:RCo, and vWF:CB was evidenced in the whole cohort (respectively
3.32 vs 2.29 IU/mL, p< 0.001 ; 2.98 vs 1.86 IU/mL, p< 0.001 ; 3.16 vs 2.16 IU/mL,
p< 0.001). Patients with pre-TAVI vWF abnormalities consistent with a type 2A vWF
syndrome preferentially improved their vWF function with respect to patients with a
normal ratio (relative increase of vWF:CB of 63.8% vs 3.5%).
Conclusions: Primary hemostasis parameters involving vWF are improved after
TAVI, especially in patients with preexisting abnormalities consistent with acquired
type 2A von Willebrand syndrome. Moreover, our observations, although limited to a
small single-center study, suggest that Heyde’s syndrome can be cured by TAVI.
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Background: We sought to identify the prevalence and prognostic impact of left
ventricular reverse remodeling (LVRR) in a non-selected high-risk patient population
with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI).
Methods: Two hundred thirty-nine consecutive patients undergoing TAVI were
enrolled in our retrospective analysis between November 2008 and December 2013.
LVRR was deﬁned as a left ventricular ejection fraction increase of 10 U or a left
ventricular ejection fraction of 50%, a decrease in indexed left ventricular end-
diastolic diameter of 10% or indexed left ventricular end-diastolic diameter of 33
mm/m2, and an interventricular septum thickness 11 mm at 7258 days.
Results: LVRR was found in 44 patients (18%). When added to a prognostic baseline
model including age, diabetes, baseline left ventricular ejection fraction and aortic valve
area, emerged as independent predictor of long-term (1.71.4 years)mortality (HR0.28,
95%CI 0.13-0.62, p¼0.002), along with diabetes (HR 4.6, 95%CI 1.5-13.7, p¼0.006).
Conclusions: Early LVRR is a predictor of long-term clinical outcome.
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Background: Trans-catheter heart valve implantation is a therapeutic option for the
treatment of patients with bioprosthetic valve failure. We aim to describe our expe-
rience using this technique in the treatment of degenerated mitral, aortic and tricuspid
bioprosthetic valves.lvular disease - Aortic: TAVR B223
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comMethods: 33 patients underwent a valve-in-valve procedure, with the implantation of
34 percutaneous implantable valves; one patient underwent the implantation of both, a
mitral and an aortic valve device during the same pracedure. Both, the Edwards-Sa-
pien and the CoreValve devices were used. Outcomes were evaluated using the VARC
2 criteria.
Results: Valve-in-Valve in the aortic position (N¼23): mean age of patients was 81.4
 5.9 years. The CoreValve and the Edwards-Sapien valve devices were used in
91.3% and 8.7% of patients, respectively. The CoreValve device was implanted via
the trans-axillar route in 3 cases and via trans-femoral route in 18 cases. The trans-
apical route was used in both Edwards-Sapien implantations. Procedural success was
achieved in 100% of cases. One month and one year survival rates were 100% and
90%; respectively. At one month follow up, 95.7% of patients were in NYHA I/II.
Valve-in-Valve in the mitral position (N¼10): mean age of patients was 73.6  15
years. All the procedures were performed with the Edwards-Sapien device via the
trans-apical route. Procedural success was achieved in 100% of cases. One month and
one year survival rates were 90% and 80%; respectively. At one month follow up,
100% of patients were in NYHA I/II. Valve-in-Valve in the tricuspid position (N¼1):
A 78 year-old patient NYHA IV, was treated with the successful trans-femoral vein
implantation of an Edwards-Sapien 29mm valve within a severely stenotic bio-
prosthetic Handcock 31mm valve. The procedure went uneventful. At one month
follow up the patient was in NYHA II. Pre- and post- peak and mean trans-valvular
gradients were 26/16 and 6/3 mmHg, respectively.
Conclusions: In our experience, the Valve-in-Valve procedure for the treatment of
failed bio-prosthetic valves, using multiple access techniques and available devices,
led to signiﬁcant symptomatic improvement, low peri-procedural morbidity and low
mortality rates.
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Background: Elevated levels of natriuretic peptides are associated with adverse
outcome across a wide spectrum of cardiovascular diseases. However, cut-off values
differ according to age, gender, and body weight. We studied the prognostic value of
plasma N-terminal pro-brain natriuretic peptide (NT-proBNP)-ratio, which is inde-
pendent of individual cut-off levels, in predicting mortality in patients undergoing
transcatheter aortic valve replacement (TAVR).
Methods: Out of 350 consecutive TAVR patients, 244 patients with pre-procedural
NT-proBNP levels were included in the analysis, and the predictive value of NT-
proBNP-ratio (measured NT-proBNP/maximal normal NT-proBNP values speciﬁc for
age and gender) on all-cause-mortality was assessed in a multivariate model.
Results: Median BNP-ratio was 4.2 [interquartile range 1.8-9.7). All-cause mortality
was 7.8% at 30 days, and 16.9% at 1 year, respectively. All-cause mortality at 30 days
was 3.4% in patients with less than median NT-proBNP-ratio, and 14.0% in patients
with more than median NT-proBNP-ratio (p¼0.02). All-cause mortality at 1 year was
7.0% in patients with less than median NT-proBNP-ratio, and 26.8% in those with
more than median NT-proBNP-ratio (p¼0.003). Cumulative survival declined with
increasing quartiles of BNP-ratio (log rank p¼0.001). All patients with a NT-proBNP-
ratio below 1.79 (62/62; 100%) survived at 1 year follow-up. In ROC analysis, NT-
proBNP-ratio signiﬁcantly predicted 30-day (AUC¼0.72; CI¼0.61, 0.83; p¼0.002)
and 1-year all-cause mortality (AUC¼0.71; CI¼0.61, 0.81; p¼0.001). By multivariate
Cox regression analysis including baseline characteristics and NT-proBNP-ratio, both
chronic obstructive pulmonary disease and NT-proBNP-ratio were the only inde-
pendent predictors of all-cause mortality.
Conclusions: NT-proBNP-clinical-activation is associated with increased short- and
long-term mortality after TAVR, and independently predicts all-cause mortality.
Hence, NT-proBNP-clinical-activation should be considered in risk stratiﬁcation for
patients undergoing TAVR.
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of the transcatheter heart valve (THV). Undersizing may result in paravalvular
regurgitation (PVR), while excessive oversizing may result in annular injury. Some
patients have a borderline annular size that ﬁts between two available THV sizes. One
strategy is intentional underexpansion of an oversized THV.
Methods: Thirty one patients underwent TAVR with an intentionally underexpanded
Sapien XT or Sapien 3 THV (Edwards Lifesciences Inc., CA, USA). THVs were
intentionally underexpanded when there was >20% computed tomography (CT)
annular area oversizing or >10% area oversizing with adverse root features. The
deployment balloon was ﬁlled with 5-10% less volume than the manufacturer’s rec-
ommended volume. Transthoracic echocardiography (TTE) and cardiac CT were
performed in all patients immediately post-implant. At 1 year, 31/31 patients (100%)
underwent repeat TTE and 22/31 (71%) underwent repeat CT.
Results: There was no signiﬁcant change in THV hemodynamics or stent size at 1
year. Mean trans-aortic gradient was 124 mmHg immediately post-implant and
126 mmHg at 1 year (p¼0.3). Mean aortic valve area was 1.70.3 cm2 imme-
diately post-implant and 1.60.5 cm2 at 1 year (p¼0.4). PVR was mild or less in
31/31 patients (100%) immediately post-implant and in 30/31 patients (97%) at 1
year. One patient had moderate PVR at 1 year. CT derived stent frame area
immediately post-implant and at 1 year was 4.90.9 cm2 and 5.10.9 cm2
respectively at stent inﬂow (p¼0.05), 5.11.0 cm2 and 5.21.0 cm2 respectively at
mid stent (p¼0.5), 5.30.9 cm2 and 5.20.9 respectively at stent outﬂow (p¼0.5).
There was no signiﬁcant difference in stent frame short and long axis immediately
post-implant versus 1 year, either at the stent inﬂow, mid stent or stent outﬂow (all
p-values >0.05).
Conclusions: There was no signiﬁcant change in THV hemodynamic function and
stent frame expansion 1 year following TAVR with an intentionally underexpanded
balloon-expandable THV. In selected patients in whom excessive oversizing is a
concern, a strategy of intentional underexpansion may reduce the risk of annular
injury without compromising valve performance.
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Background: Transcatheter aortic valve implantation (TAVI) is a minimally invasive
alternative to surgical aortic valve replacement (SAVR) in high risk surgical patients.
Pooled meta-analysis was attempted to analyze the risk of developing permanent heart
block following TAVI.
Methods: All electronic databases were queried for published studies on TAVI and
SAVR. Studies reporting the outcomes of TAVI procedure were included. Exclusion
criteria applied was: studies lacking SAVR as controls, studies comparing trans-apical
versus trans-femoral TAVI procedures and studies not reporting on the outcome of
heart block or pacemaker implantation.
Results: A total of 21 studies with a total of 5061 patients were included in the
study and 2692 of these had TAVI. The risk of permanent heart block necessitating
pacemaker implantation was very high in the patients undergoing TAVI comparedtember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
